The management of non-small cell lung cancer has undergone major transformation in the last three years driven by the increasing using of immunotherapy as well as local ablative therapies in advanced stage disease.  Translation of these practices into community based setting is important as overa

This course is a collection of multidisciplinary experts providing updates on research that has helped redefine practice paradigms for patient-focused individualized care in gynecological cancers.

In this course, four expert speakers will fulfill the above educational needs by: 1) Highlighting ways in which older adults differ from younger healthier patients, and how they are under-represented in standard setting trials.

Soft tissue sarcomas are rare and involve a well-integrated multi-modality approach to optimize outcomes and decrease morbidity.

This course pulls together international experts in the use of hypofractionation for head and neck cancer, using a case based approach to illustrate common clinical scenarios.

There is significant interest in the potential of combining immunooncology drugs (IO) with radiotherapy (RT).

Patient Reported Outcomes (PROs) are often minimized as bulky processes that require time for patients to fill out and impose further administrative burdens on providers. This is not necessarily so.

This course will present four challenging brain metastases cases and variations thereof that speak to the following themes: multiple brain metastases, brain metastases responsive to systemic therapy agents, complications of radiotherapy including neurocognitive effects, and large radiotherapy tar

Liver cancer incidence is growing faster than any other cancer in men and women. It is evident that the optimal care of patients with HCC necessitates the involvement of a multidisciplinary team utilizing evidence-based cancer guidelines.

Over the last three years, results have been reported on large and/or national/international clinical trials in pediatric CNS tumors and radiotherapy.